Note: Descriptions are shown in the official language in which they were submitted.
CA 02459492 2004-03-03
SPECIFICATION
Anti-influenzal Agent
Background of the Invention
The present invention relates to an anti-influenzal agent. More
specifically, the present invention pertains to an agent for treating or
preventing influenza virus- infectious diseases.
Influenza virus is one of the most commonly encountered infectious
pathogen and it may become a cause of considerably high prevalence and
mortality rate, in particular, in the aged, the infant, persons suffering from
chronic diseases, and persons suffering from immune deficiency diseases
(Ref. 1, 2).
There have been reported three types of influenza viruses A, B and C_
In this respect, it has been known that the A type influenza virus widely
prevails and shows strong pathogenicity, while the B and C type influenza
viruses rather regionally or locally prevail and show weak pathogenicity
However, it may be recognized that there is a common infection mechanism
in the infection of these three types of influenza viruses.
Ref.l: Kim HW, Brandt CD, Arrobio JO, Murphy B, Chanock RM, Pa
rrott RH, Influenza A and B virus infection in infants and young ch;_1dr
en during the years 1957-1976, Am. J. .pid~miol., 1979, 109: 4G4-479.
Ref.2: Barker WH, Mullooly JP, Impact of epidemic type A influenza i
n a defined adult population, Am.~ F.pidemiol.. 1980, 112: 798-813.
The pathogenicity of the influenza virus is determined by the
polymorphism of the individual virus genome and the trypsin-type proteases
secreted by host cells of the respiratory tract, which allow the virus genome
invade into the cytoplasm of the host cells. The trypsin-type protease is
1
CA 02459492 2004-03-03
secreted as a result of the induction of the membrane fusion activity of
influenza virus due to the limitative cleavage of mainly viral envelope
glycoproteins [hemagglutinin (HA)] and the corresponding fusion of viral
membrane and cytoplasmic membrane (R.ef. 3-5).
Re~3: Klenk HD, Garten W, Host cell proteases controlling virus
pathogenicity, Trends Microbiol., 1980, 2: 39-43.
Ref.4: Klenk HD, Rott R, The molecular biology of influenza virus pat
hogenicity, Adv. Virus _R_es., 1988, 34: 247-281.
Ref.S: Homma M, Ohuchi M, Trypsin action on the growth of Sendai
virus in tissue culture cells, J_J_ Virol., 1973, 12: 1457-1465.
The cleavage of the viral envelope glycoprotein takes place on the
membrane of epithelial cells of the respiratory tract and/or the respiratory
cavity (R,ef. 6, 6).
Ref.G: Kido H, Yokogoshi Y, Sakai K, Tashiro M, Kishino Y, Fukutomi A,
Kutunuma N, Isolation and characterization of a novel trypsin-like protease
found in rat bronchiolar epithelial Clara cells, J. 3iol. Chem.; 1992, 2G7:
13573-13579.
Ref.7: Tashiro M, Yokogoshi Y, Tobita K, Seto JT, Rott R, Kido H, Tryp
tase Clara, an activating protease for Sendai virus in rat lungs, is invo
lved in pneumopathogenicity, Viro _. 1992, GG: 7211-7216.
The activity of the protease capable of cleaving the viral envelope
glycoprotein is strictly controlled by endogeneous inhibitory compounds for
the foregoing protease included in the fluids secreted from the respiratory
tract such as the mucosal protease inhibitor (MPI; Ref. 8) in the upper
respiratory tract and the pulmonary surfactant (PS; Ref. 9). The surfactant
protein A (SP-A) included in the PS of the lung belongs to type C lectin to
which sialic acid is added and this protein is directly linked to inRuenza
virus HA to thus inhibit any invasion of viruses in cells (R.ef. 10). In
addition
2
CA 02459492 2004-03-03
to these compounds included in the secreting fluids of the respiratory tract,
the mucosal immune system serves as a principal immunological defensive
system for preventing any invasion of viruses into cells and more
specifically,
the induction of local secretion of immunoglobulins IgA and IgG is closely
related to the protection from the influenza virus infection (R,efs. 11-13).
These results would suggest that the concentrations of these anti-viral bio-
protective substances included in the fluids secreted by the respiratory tract
determine the susceptibility of individuals to the influenza virus infection.
Ref.B: Beppu Y, Imamura Y, Tashiro M, Towatari T, Ariga H, Kido H, Human
Mucus protease inhibitor in airway fluids is a potential defensive compound
against infection with influenza A and Sendai viruses, J Biochem.. 1997,
121: 309-31G.
Ref.9: Kido H, Sakai K, Kishino Y, Tashiro M, A pulmonary surfactant
is a potential endogenous inhibitor of proteolytic activation of Sendai v
irus and influenza virus, FFBS T.e . .~ 1993, 322: 115-119.
Ref.lO: Benne CA, Kraaijeveld CA, van Strijp JAG, Brouwer E, Harms
en M, Verhoef J, van GoldLMG, van Iwaarden JF, Interactions of surfa
ctant protein A with influenza A viruses: binding and neutralization, ~.
TnfPC~.t.~i .._ 1995, 171: 335-341.
Ref.ll: Liew FY, Russell SM, Appleyard G, Brand CM, Beale J, Cross-
protection in mice infected with influenza A virus by the respiratory ro
ute is correlated with local IgA rather than serum antibody or cytotoxic
T cell reactivity, Fu aT. Tmmunol., 1984, 14: 350-356.
Ref. l2: Tamura S, Funato H, Hirabayash Y, et al., Functional role of r
espiratory tract hemagglutinin-specific IgA antibodies in protection agai
nst influenza, ~.cine. 1990, 8: 479-485.
Ref. i3: 4~%righi PF, iviurphy BR, Kervina ivl, Lawrence Eln, Fhelan MA,
Karzon DT, Secretory immunological response after intranasal inactiva
3
CA 02459492 2004-03-03
ted influenza A virus vaccinations: evidence for immunoglobulin A mem
ory, Infect. Immun.. 1983, 40: 1092-1095.
Ambroxol (2-amino-3,5-dibromo-N-[trans-4-hydroxy cyclohexylJ
benzyl amine) known as an expectorant or a sputum-dissolving agent has
been used for treating chronic bronchitis and respiratory distress syndrome
of newborn (Ref. 14).
It has been reported that ambroxol has such pharmacological
functions as the control of mucus on the adenocyte of the respiratory tract
and the promotion of the PS-production (R,ef. 15).
Moreover, ambroxol also shows an antioxidant function (R,e~ 1G) and
an anti-inflammatory function associated with the reduction of inflammatory
cytokines released from the bronchial alveolar macrophages, monocytes and
gr anulocytes (Refs. 17, 18). However, there has not yet been known any
function of ambroxol on the in vivo influenza virus infection.
Bromhexin (2-amino-3,5-dibromo-N-cyclohexyl-N-methylbenzyl ami
ne) known as an expectorant has been used for treating chronic bronch
itis. However, there has not yet been known any function of bromhexin
on the in vivo influenza virus infection.
Ref. l4: Germouty J, Jirou-Najou J, Clinical efficacy of ambroxol in the
treatment of bronchial stasis, R.~ ; ~a ion. 1987, 51: 37-41.
Re~ 15: Heath MF, Jacobson W, The inhibition of lysosomal phospholipase A
from rabbit lung by ambroxol and its consequences for pulmonary surfactant,
1985, 1G3: 337-44.
Ref.lG: Gillissen A, Scharling B, Jaworska M, Bertling A, Rasche K, Sc
hultze-Werninghaus G, Oxidant scavenger function of ambroxol in vitro:
a comparison with N-acetylcysteine AC, ~ . Med. ~Prl). 1997, 1
96: 389-398.
Ref.l7: Pfeifer S, Zissel G, Kienast K, Muller-~,luernheim J, Reduction o
4
CA 02459492 2004-03-03
f cytokine release from blood and bronchoalveolar mononuclear cells by
ambroxol, F:ur. ~T. Med. _R_.es.. 1997, 2: 129-132.
Ref.lB: Gibbs BF, Schmutzler W, Vollrath IB, Brostharardt P, Braam U,
Wolff HH, Zadlo-Klarwasser G, Ambroxol inhibits the release of histam
ine, leukotrienes and cytokines from human leukocytes and mast cells,
Infl amm. Res.. 1999, 48: 86-93.
Disclosure of the Invention
It is an object of the present invention to provide an anti-in~luenzal
agent or an agent for treating or preventing influenza virus infectious
diseases, while making use of the defensive effect, against the influenza
virus infection, of ambroxol and/or bromhexin, which has an antioxidant
effect and can serve as a sputum-dissolving agent capable of promoting the
release of PS.
The gist of the present invention resides in an anti-influenzal agent
comprising, as an effective component, ambroxol, or a pharmaceutically
acceptable salt thereof.
The agent of the present invention is characterized in that it possesses
an anti-influenzal effect through promoting the secretion of a biological or
in
vivo factors (a group of bio-protective substances) showing an anti-influenza
virus function and included in the fluid secreted from the respiratory tract.
In other words, the present invention herein provides an anti-influenzal
agent characterized in that the agent comprises, as an effective component,
ambroxol, bromhexin or a pharmaceutically acceptable salt thereof and that
it possesses an anti-influenza) effect through promoting the secretion of a
biological or in vivo factors (a group of bio-protective substances) showing
an
anti-inRuenza virus function and included in the ~.uid secreted from the
respiratory tract.
5
CA 02459492 2004-03-03
Moreover, the agent of the present invention is characterized in that
the proliferation of influenza virus in the respiratory tract is controlled by
promoting the secretion of substances capable of inhibiting the protease
present in the respiratory tract, which can induce the infectiousness of
influenza virus and the mucosal immune substances such as IgA and IgG
and more specifically, the present invention herein provides an anti-
influenzal agent characterized in that the anti-influenza) agent comprises,
as an effective component, ambroxol, bromhexin or a pharmaceutically
acceptable salt thereof and that the proliferation of influenza virus in the
respiratory tract is controlled by promoting the secretion of biological
factors
showing anti-influenza virus function and included in the fluid secreted from
the respiratory tract, such as MPI and PS, and the mucosal immune
substances such as IgA and IgG.
Further, the agent of the present invention is characterized in that it
can inhibit the release of inflammatory cytokines in the respiratory tract and
more specifically, the present invention also provides an anti-influenza)
agent characterized in that the agent comprises, as an effective component,
ambroxal, bromhexin or a pharmaceutically acceptable salt thereof and that
it can inhibit the proliferation of influenza virus through promoting the
secretion of anti-influenza virus factors included in the fluids secreted in
the
respiratory tract such as MPI andlor PS as well as the secretion of mucosal
immune substances such as IgA and/or IgG and that it can inhibit the
release of inflammatory cytokines in the respiratory tract.
The anti-influenza) agent of the present invention serves as an agent
for treating or preventing influenza virus-infectious diseases.
The present invention also provides use of ambroxol, bromhexin or a
pharmaceuticali.y acceptable salt thereof for the preparation of anti-
influenzal agent.
G
CA 02459492 2004-03-03
The present invention further provides a method of treating influenza
virus-infectious diseases which comprises administering an anti-influenzal
agent comprising ambroxol, bromhexin or a pharmaceutically acceptable salt
thereof as an effective component to patients suffering from the diseases.
Brief Description of the Drawings
Fig. 1 is a diagram showing the fact that ambroxol improves the
surviving rate of mice infected with influenza A virus.
Fig. 2 is a diagram for illustrating the effect of ambroxol to inhibit the
viral proliferation in BALF (A) or the pulmonary lesions visually observed in
mice after 4 days from the infection with the virus (B).
Fig. 3 is a diagram for illustrating the effect of ambroxol to stimulate
the secretion of the mucous immunoglobulin IgA in BALF of a group of un-
infected mice (A), or a group of mice infected with influenza A virus (B).
Fig. 4 is a diagram for illustrating the effect of ambroxol to stimulate
the secretion of the mucous immunoglobulin IgG in BALF of a group of un-
infected mice (A), or a group of mice infected with influenza A virus (B).
Best Mode for Carrying Out the Invention
Regarding ambroxol (2-amino-3,5-dibromo-N-[trans-4-hydroxy
cyclohexyl] benzyl amine), the hydrochloride thereof represented by the
following chemical formula 1 (general name: ambroxol hydrochloride;
chemical name: trans-4-[(2-amino-3,5- dibromo-benzyl) amino] cyclohexanol
hydrochloride) has widely been used in the world including Germany as an
expectorant or a sputum-dissolving agent and has been used for treating
chronic bronchitis and respiratory distress syndrome of newborn, as has
been aiscussed above.
[Chemical Formula 1]
7
CA 02459492 2004-03-03
g CH~htfi _ _ _ _pH
~H~
Br
Also, regarding bromhexin (2-amino-3,5-dibromo-N-cyclohexyl-N-
methylbenzyl amine), the hydrochloride thereof represented by the following
chemical formula 2 (general name: bromhexin hydrochloride; chemical name:
2-amino-3,5-dibromo-N-cyclohexyl-N-methylbenzyl amine hydrochloride)
has widely been used in the world including Germany as an expectorant and
has been used for treating chronic bronchitis, as has been discussed above.
[Chemical Formula 2]
1~
~3
B~- CB~t3
l~~
Br
The viral infectious diseases capable of being treated with and/or
prevented by the agent according to the present invention may be any one
inasmuch as they are caused through the infection of the respiratory tract
with viruses having outer membrane glycoproteins and specific examples
8
CA 02459492 2004-03-03
thereof are diseases attributable to influenza viruses, par a-influenza
viruses,
respiratory syncytial viruses, measles viruses or mumps viruses.
The anti-infl.uenzal agent of the present invention can be
administered to a patient in a variety of dosage forms, like the usual
pharmaceutical compositions, for instance, orally administered solid
pharmaceutical preparations such as tablets, powders, fine granules,
granules, capsules, suspensions, troches and chewable preparations, and
liquid preparations such as elixirs and syrups (including dry syrups).
Alternatively, if the oral administration thereof is ill-fitted for a patient
or in
case where it is desired to ensure more rapid and reliable efficacy through
the selection of local administration, the anti-influenzal agent of the
present
invention is administered according to the methods conventionally used such
as injection of liquid preparations, spraying of mist, injection using a
nebulizer, the administration by a dry powder device (DPD) using a
spinhaler or a diskhaler or the administration by a metered dose inhaler
(MDI). In this respect, these methods are selected and used while taking into
consideration, for instance, facilities, reliability and effectiveness.
The dose or dosage, to be administered, of the anti-influenzal agent of
the invention may appropriately be controlled depending on the dosage
forms of the desired pharmaceutical preparations.
The anti-inffuenzal agent of the invention may be administered to a
patient in a daily dose in portions over one or several times per day if it is
in
the dosage form of an orally administered solid preparation such as a tablet
or an orally administered liquid preparation. In case of the dosage forms, for
infants, to be taken at one dose, such as a syrup, a troche and a chewable
tablet, which are pharmaceutical preparations for simultaneously enjoying
their local effects and systemic effects through the internal use thereof, it
is
sufficient to incorporate 1/2 to 1/10 time the daily dose into the agent in
the
9
CA 02459492 2004-03-03
foregoing dosage forms prior to use the same. In this case, the total dose
thereof may be less than the daily dose. Contrary to this, such an amount of
the effective component as that corresponding to the daily dose may be
formulated into a single dose, inasmuch as it is not unreasonable from the
viewpoint of the dosage form of the pharmaceutical preparation. In addition,
in case of, for instance, the administration of an injectable liquid
preparation,
an agent administered by a mist-spray device, the administration by a
nebulizer or the administration by the powder inhalation, the agents may be
prepared in such a manner that they contain the effective component in an
amount of 1/10 to 1/100 time the dose for the orally administered agent for
internal use.
In the preparation of these agents, a variety of currently used
additives may be employed, such as a filler, a thickening agent, a binder, a
disintegrator, a surfactant, a lubricant, a coating agent, a sustained release
agent, a diluent and/or an excipients. In addition to the foregoing, the agent
of the present invention may, if necessary, further comprise other additives
such as a solubilizing agent, a buffering agent, a preservative, a
solubilizer,
an isotonicity, an emulsifying agent, a suspending agent, a dispersant, a
thickener, a gelatinizing agent, a hardening agent, an absorbent, an
adhesive, an elasticizing agent, an adsorbent, a perfume, a coloring agent, a
corrigent, an antioxidant, a humectant, a light-screening agent, a brightener
and/or an anti-static agent.
More specifically, examples of such additives include an excipient such
as lactose, corn starch, mannitol, D-sorbitol, crystalline cellulose,
erythritol
and sucrose; a binder such as hydroxypropyl cellulose (HPC-L),
hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, methyl cellulose and
gelatinized starch; a disintegrator such as calcium car boxymethyl ceiiuiose,
sodium cross carboxymethyl cellulose and crosslinked polyvinyl pyrrolidone;
CA 02459492 2004-03-03
a lubricant such as magnesium stearate and talc; a perfume, for instance, a
flavor or an aromatic oil such as 1-menthol, vanillin, lemon oil, cinnamon oil
and mentha oil; and/or an adsorbent such as synthetic aluminum silicate and
light anhydrous silicic acid. Moreover, it is also possible to prepare coated
pharmaceutical preparations through the use of a currently used coating
agent such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose,
methyl cellulose or polyvinyl pyrrolidone. If necessary, a sweetener may
likewise be used, in particular, in troches, syrups and chewable preparations
among others. Specific examples of such sweeteners are mannitol, glucose,
maltose, starch syrup, malt extract, maltitol, sorbitol, sucrose, unrefined
sugar, fructose, lactose, honey, xylitol, hydrangea tea, saccharin, aspartyl
phenylalanine ester and other malto-oligo saccharides, and oligo sacchaxzdes
such as maltosyl sucrose, isomaltyrose of reduced type and raffinose.
Pharmaceutical preparations containing these additives may be prepared
according to any method known in this field, currently used ones or ordinary
ones depending on the dosage forms thereof.
Regarding the powdery and granular preparations such as the
powders, fine granules and granules (including those administered by a
metered dose inhaler (MDI) or a dry powder device (DPD)], they may
appropriately be prepared, while taking into consideration various
properties such as the dustability and adhesiveness. For instance, they are
preferably prepared, while taking into consideration physical properties
thereof such as the bulk, dustability, adhesiveness, hygroscopicity, charging
ability, wettability and solubility of each powdery substance as well as other
properties such as the particle size (particle diameter), surface area and
shapes of particles. Specifically, in the powder inhalation, one should pay a
special attention to the particle size of the arug components in order to
effectively make the drug arrive at the affected site and accordingly, the
most
11
CA 02459492 2004-03-03
suitable particle size thereof should range from 0.5 to 5.0,u m. Moreover, it
is
also preferred to prepare the agent while taking into consideration, for
instance, the easy handling ability, and prevention of hygroscopicity,
decomposition behaviors, denaturation and discoloration. The powder may
be prepared according to any known pulverization method such as dry
pulverization, wet pulverization, low temperature pulverization, jet
pulverization, batchwise pulverization, continuous open circuit-
pulverization and continuous closed circuit-pulverization methods, which
may be used alone or in any combination, depending on purposes.
It is recognized that ambroxol and bromhexin shows an effect of
promoting the secretion of antiviral factors in the respiratory tract and in
turn has an effect of inhibiting the proliferation of influenza viruses in the
respiratory tract. The effect of ambroxol would be proved by referring to the
facts that it can increase the concentrations of virus proliferation-
inhibitory
substances such as SP-A, MPI, IgA and IgG in the respiratory tract and that
it can inhibit the release of inflammatory cytokines in the fluid secreted in
the respiratory tract.
Examples
The present invention will hereunder be described in more detail with
reference to the following Examples, but the present invention is not
restricted to these specific Examples at all.
Example
<Summary>
Ambroxol serving as a sputum-dissolving agent, which had an
antioxidant action and induced the release of PS was inspected for the effect
of protecting a subject from the infection with inr~uenza virus, using mice.
After infecting the nasal cavities of mice with a lethal dose of influenza
12
CA 02459492 2004-03-03
A/AichiG8 (H3N2) viruses, ambroxol or an excipient was intraperitoneally
administered to those mice twice a day and then there were determined or
analyzed the surviving rate, the titer of virus in BALF, the cytokines and
antiviral factors present in BALF or the mucosal immunoglobulins IgA and
IgG, as well as the concentrations of PS and MPI.
As a result, it was found that ambroxol significantly inhibited the
proliferation of the virus and considerably improved the surviving rate of the
infected mice. Regarding the determination of the surviving rate, the effect
of
ambroxol reached the maximum level at a dose of 10 mg/kg/day and was
reduced at the dose higher than the dose specified herein. In case of such a
higher dose, however, the surviving rate of mice was improved as compared
with that observed for the physiological saline-administered animal group
used as a control. The infection with influenza virus induced the release of
antiviral factors and inflammatory cytokines in the fluid secreted from the
respiratory tract and ambroxol further promoted the release of these
antiviral factors. However, it also promoted the release of a trypsin-type
protease, which would promote the virus-proliferation. Moreover, ambroxol
temporarily inhibited the release of cytokines or tumor necrosis factor- a
(TNF- a ), interferon- y (IFN- y ) and interleukin-2 (IL-2) in the fluid
secreted in the respiratory tract.
It has been recognized that ambroxol has several negative effects
involved in the virus proliferation in vivo, but as a whole, it can
significantly
increase the level of a group of substances in the respiratory tract, which
can
control the virus proliferation and this clearly suggests that it can
clinically
be applied as an effective agent for treating a patient infected with
influenza
virus.
After infecting the nasal cavities of mice with a lethal dose of mouse-
adaptive type influenza A/AichiG8 (H3N2) viruses, ambroxol was
13
CA 02459492 2004-03-03
administered to those mice and then there were determined or analyzed the
surviving rate, the titer of virus, and the virus proliferation and the
concentrations of a trypsin type protease, MPI, PS, IgA, IgG and cytokines in
the fluid secreted in the respiratory tract.
<Subject and Methods>
1) Animals and Subjects
Three-week-old female oddY mice each having a body weights ranging
from 8 to 10 g and free of any speci~.c pathogen were purchased from Japan
SLC Inc. (Shizuoka, Japan). All of the mice were treated on the basis of the
Guideline for Animal Experiments, Tokushima University. Boehringer
Ingelheim furnished the inventors of this invention with ambroxol. Trypsin
originated from the porcine spleen was purchased from Sigma Company. The
mouse-adaptive type influenza A/AichiG8 (H3N2) viruses (Ref. 19) were used
after the proliferation thereof in 10-day-old embryo-containing eggs.
Ref. l9: Ovcharenko AV, Zhirnov OP, Aprotinin aerosol treatment of influenza
and paramyxovirus bronchopneumonia of mice, An_ .l 'ral. R. , 1994, 23:
107-118.
2) Infection with Virus and Method for Administering Ambroxol
The nasal cavities of mice were infected with the influenza A/Aichi/68
(H3N2) viruses of G.6 X 104 plaque-forming units (PFU) at a dose of 20 a 1,
under the anesthetization with ether. Within 10 to 15 minutes immediately
after the virus infection, 200 ,u 1 of ambroxol mixed with a common salt
aqueous solution was intraperitoneally administered to each group (10
animals each) of animals at a dose of 2, 5, 10 or 15 mg/kg body weight.
Thereafter ambroxol was administered to these groups of animals according
to the same procedures used above twice a day over 7 to 10 days. In
experiments for determining or analyzing a variety of compounds present in
the fluid secreted from the respiratory tract and a variety of desired
14
CA 02459492 2004-03-03
pathological changes of the same, three groups of animals were selected to
treat them with ambroxol at doses of 0, 10 and 30 mglkg/day, respectively.
Each group comprised 80 animals. The level of viruses present in BALF was
determined according to the immunoffuorescent cell-counting method) as has
previously been reported (R.ef. 20).
Ref.20: Tashiro M, Homma M, Pneumotropism of Sendai virus in relation to
protease-mediated activation in mouse lungs, Infect. Immun., 1983, 39: 879-
888.
3) Preparation of BALF
The animals used in this test were divided into the following groups
(each including 80 animals): a group treated with ambroxol, a group free of
any such treatment, a group infected with influenza virus and a group free of
any influenza virus- infection. At least 5 animals were selected from each
test group every day to thus collect BALF (according to the method of Singh
et al. (Ref. 21)) over 7 days. The samples of BALF were stored at -80°C
till
they were practically used.
Ref. 21: Singh G, Katyal SL, An immunologic study of the secretory pr
oducts of rat clara cells, J. Histochem. Cytochem., 1984, 32: 49-54.
4) Determination of the level of SP-A, Cytokine and Immunoglobulin in
BALF
There is a homology of 95% between the SP-A amino acid sequences of
mouse and rat (R,efs. 22, 23) and the isolated polyclonal antibody for the
rat's
SP-A (R,efs. G, 24) reacted with the mouse SP-A. Thus, an enzyme-linked
immunosorbent assay (ELISA) system was constructed using specific
antibodies for non-biotinylated and biotinylated rat's SP-A and the
concentration of the SP-A in mouse BALE was analyzed using mouse SP-A as
the reference material for preparing a calibration curve. The levels of
cytokines [TNF- cx , IL-2, IFN- y , interleukin-G (IL-G), interleukin-4 (IL-
4)]
CA 02459492 2004-03-03
present in BALF were determined using ELISA kits (available from Bio-
Source International, CA, USA) according to the manufacturer's protocol.
The levels of IgA and IgG present in BALF were likewise determined using
ELISA kits (available from Bethyl Company, TX, USA). In this connection,
absorbances observed at 490 nm and 450 nm were read by Immuno Mini
NJ-2300 Multi-plate-Reader.
Ref. 21: Singh G, Katyal SL, An immunologic study of the secretory pr
oducts of rat clara cells, T-H; .o .h .m Cy .o h .m.. 1984, 32: 49-54.
Ref.22: Korfhagen TR, Bruno MD, Glasser SW, et al. Murine pulmonar
y surfactant SP-A: gene cloning, sequence, and transcripitional activity,
Am. J. Physiol.. 1992, 263: L54G-554.
Ref. 23: Lacaze-Masmonteil T, Fraslon C, Bourban J, Raymondjean M,
Kahn A, Characterization of the rat pulmonary surfactant protein A pr
omoter, Eur. J. Biochem.. 1992, 206: 613-623.
Ref.24: Sakai K, Kweon MN, Kohri T, Kishino Y, Effects of a pulmona
ry surfactant and surfactant protein A on phagocytosis of fractionated a
lveolar macrophages: relationship to starvation, CeL. Mol. Biol., 1992, 3
8: 123-130.
5) Determination of Enzymes and Inhibitors
As has been described above (Kido H, Yokogoshi Y, Sakai K, Tashiro M,
Kishino Y, Fukutomi A, Kutunuma N, Isolation and characterization of a
novel trypsin-like protease found in rat bronchiolar epithelial Clara cells,
J.
Biol. Chem., 1992, 267:13573-13579), the trypsin type protease was
determined using a sequence: N-tert- butoxycarbonyl-Gln-Ala-Arg-4-metyhl-
coumaryl-7-amide similar to the consensus cleavage motif of the influenza
virus HA. The inhibitory activity of MPI, which corresponded 90% of the
substances inhibiting the influenza virus HA-cleaving proteases preseni in
BALF (Refs. 25, 2G) was determined as follows: MPI was treated with a 5%
1G
CA 02459492 2004-03-03
(v/v) perchloric acid solution, while making use of the stability of MPI to
acids and heat, the mixture was centrifuged to remove most of the proteins
present therein and to collect the supernatant of BALF and then the latter
was boiled at 100°C for 10 minutes. Thereafter, the resulting
supernatant
was centrifuged at 1500 X g for 15 minutes, followed by adjusting the pH
thereof to 7.0 with 4M KOH and determination of the protease-inhibitory
activity of the supernatant according to the method previously proposed
(Beppu Y, Imamura Y, Tashiro M, Towatari T, Ariga H, Kido H, Human
Mucus protease inhibitor in airway fluids is a potential defensive compound
against infection with influenza A and Sendai viruses, J. Biochem., 1997,
121: 309-316).
Ref.25: Stolk J, Rossie W, Dijkman JH, Apocynin improves the efficacy
of a secretory leukocyte protease inhibitor in experimental emphysema,
Am. J_ Resx~ir. Crit. Care Med., 1994, 150: 1628-1631.
Ref. 2G: Ohlsson K, Tegner H, Akesson U, Isolation and partial charac
terization of a low molecular weight acid stable protease inhibitor from
human bronchial secretions, Hoppe Seylers Z. Physiol. Chem., 1977, 35
8: 583-589.
<Statistical Treatment>
All of the results obtained are expressed in terms of the average~SD.
The significant difference between the group treated with ambroxol and the
group free of such a treatment or the control was evaluated using Paired
Student's t-Test and the value P<0.05 was deemed to be significant.
<Results>
1) Ambroxol substantially improved the surviving rate of mice infected with
influenza virus.
T he resuiis pioiied on F ig. i clearly indicate that ambroxol increases
the surviving rate of the mice infected with the influenza A/Aichi/G8 (H3N2)
17
CA 02459492 2004-03-03
virus. In respect of the results plotted on Fig. l, mice were infected with
G.G
x 104 PFU of influenza A/Aichi/G8 (H3N2) virus and then the mice were
injected with an aqueous common salt solution (~), 4 mg/mg/kg/day (~1), 10
mg/mglkg/day (~), 20 mg/kg/day (D) and 30 mg/kg/day (0) of ambroxol,
intraperitoneally. Thus the surviving rate of each group of test animals (each
group consisted of 10 animals) was analyzed or monitored over 10 days.
As has been discussed above, there has been reported that ambroxol
stimulates the lung and the main bronchus to secrete PS and that it has an
anti-oxidative effect and anti-inflammatory characteristics. The effect of
ambroxol on mice infected with the influenza A/Aichi/G8 (H3N2) virus, which
shows a high infectivity and a strong progressiveness, was analyzed or
evaluated in the light of the foregoing knowledge. Mice each having a body
weight ranging from 8 to 10 g were intra-nasally infected with influenza A
viruses in an amount corresponding to the lethal dose thereof and ambroxol
was intraperitoneally injected into these animals in a variety of doses twice
a
day. Ambroxol per se was not toxic up to a dose of 30 mg/kg/day.
A significant decrease of the body weight of each animal was observed
after two days from the virus-infection and all of the test animals (n = 10),
which had not been treated with ambroxol, were killed within 10 days. In the
groups treated with ambroxol, the surviving rate of the infected mice was
improved depending on the dose of ambroxol. More specifically, the surviving
rate reached a peak value at a dose of 10 mglkglday, but the surviving rate-
improving effect of ambroxol was reduced at a dose higher than that dose
(see Fig. 1). When treating mice with ambroxol at a dose of 10 mg/kg/day, a
half of the infected mice survived although they were infected with the lethal
dose of the virus.
2) in the test animal groups treated with ambroxol, any virus-proliferation
was inhibited.
18
CA 02459492 2004-03-03
Fig. 2 shows the effect of ambroxol for inhibiting any virus-
proliferation in BALF (A) and the lesions visually observed in the mice after
4 days from the influenza virus-infection (B).
A: Mice in each group (80 animals) were infected with influenza A/Aichi/G8
(H3N2) virus and then treated with an aqueous common salt solution (1)
and 10 mg/mg/kg/day (D) and 30 mg/kg/day (~) of ambroxol as is described
later in the explanation of Fig. 1. After the infection and the treatment,
BALF was collected from 5 survived mice every day over 7 days. The titer of
virus in BALF was determined according to the foregoing immunofluorescent
cell-counting method (R.e~ 20) and the results obtained were expressed in
cell infecting unit (CII~. These data are expressed by the average~SD (n =
5). The significant difference between the values observed for mice treated
with the aqueous common salt solution and ambroxol was determined by
conducting Student's t-Test. *P<0.01.
B: Pulmonary lesions of mice visually observed for the lungs of the animals
belonging to the un-infected group after 4 days (n = 5) (1), the lungs of the
animals belonging to the group infected with influenza viruses and treated
with the aqueous common salt solution (2), and the lungs of the animals
belonging to the groups infected with influenza viruses and treated with 10
mg/kg/day (3) and 30 mg/kg/day of ambroxol.
The titer of virus in BALF was determined according to the foregoing
immunofluorescent cell-counting method in order to elucidate the basic
mechanism of ambroxol to improve the surviving rate of the infected mice.
After 2 days from the intranasal infection of mice with influenza A
viruses, the viral titer in BALF began to increase, reached the maximum
value after 5 days from the infection, the viral titer in BALF was rapidly
reduced on and after the G'-'-' day and the titer observed on the T-''- day
was
almost identical to that observed after two days from the infection. It would
19
CA 02459492 2004-03-03
be assumed that this is a result of the immunological reaction in the host
(see Fig. 2A). In the group treated with ambroxol at a dose of 10 mg/kglday,
the virus-proliferation was significantly inhibited, but the virus-
proliferation-inhibitory effect observed for the group treated with ambroxol
at a dose of 30 mg/kg/day was inferior to that described above. The test
animals were inspected for the pathological changes of the lungs or the
visual pulmonary lesions on the 4~'' day from the virus-infection (see Fig.
2B).
There were observed, in the infected mice, severe and wide-spreading liver-
like lesions on the lungs along with the rubefaction. On the other hand, in
the group treated with ambroxol at a dose of 10 mg/kg/day, the pathological
changes were distinctly reduced and the lesion-inhibitory effect of ambroxol
at a dose of 30 mg/kg/day was lower than that specified above.
The virus-proliferation in the infected mice was almost ceased and the
viruses were eliminated from the respiratory tract on the 7th day, but the
pathological changes in the lung were maintained even after the virus
proliferation had been ceased with a slight progress and the animals were
killed within 10 days. In order to elucidate the mechanism of the
improvement in the surviving rate of the infected mice and that of the
contribution of ambroxol to the virus-proliferation-inhibitory effect, the
inventors of this invention investigated the effect of ambroxol on a variety
of
cellular factors and inflammatory cytokines present in BALF and controlling
the replication of influenza viruses.
3) Effects of ambroxol on the concentrations of influenza virus-replication
promoting and -inhibitory factors present in the fluid secreted in the
respiratory tract.
The trypsin-type protease secreted in the respiratory tract such as
Tryptase Clara cleaves HA of influenza virus into HA1 and HA2 and as a
result, the protease may activate the viral membrane-fusing ability and
CA 02459492 2004-03-03
promote the viral replication (Ref. G, 7). Endogeneous inhibitory substances
such as MPI (Ref.B) and PS (R,e~9) inhibit this protease activity. For this
reason, the inventors investigated the effect of ambroxol on the
concentrations of these inhibitory substances in BALF. The results thus
obtained are summarized in the following Table 1 (Effect of ambroxol on
trypsin-like protease activity, PS and MPI in BALF originated from mice
infected with influenza A viruses).
The trypsin-type protease is in general secreted in the un-infected
mice and rats in an amount greater than those of the protease-inhibitory
substances in the respiratory tract and therefore, the respiratory tract is
always ready for the infection with influenza viruses (Refs. G, 9). When these
animals were infected with influenza viruses, the concentration of the
trypsin-type protease reached the peak value after G days from the infection
on the order of about G.4 times that observed for the un-infected animals. In
the group treated with ambroxol at a dose of 10 mg/kg/day, the secretion of
the protease was already accelerated on the 15' day and the level of the
protease reached the peak value on the 5"' day from the initiation of the
treatment. In the group to which ambroxol was administered at a dose of 30
mg/kg/day, the level of the protease was further increased, but it reached the
peak level within a shorter period of time or on the 4"' day and thereafter,
there was observed such a tendency that it was rapidly reduced. Even in the
un-infected mice, it was recognized that the secretion of the trypsin-type
protease in BALF was promoted due to the action of ambroxol (see the data
listed in Table 2). In the test animal groups to which ambroxol was
administered at doses of 10 and 30 mg/kg/day, the trypsin-type protease
levels reached their peak values on the 4"' day or up to 2.2 times and 2.4
times that observed for the un-infected animals.
The inventors further investigated the effect of ambroxol on the levels
21
CA 02459492 2004-03-03
of SP-A and MPI [see the data listed in the following Tables 1 and 2 (the
effect of ambroxol on the trypsin-like protease activity, PS and MTI in the
mouse BALF in the influenza virus-infected group and the un-infected
group)].
The infection with influenza viruses increased the levels of bio-
protective substances or SP-A and MPI each having an anti-influenzal
activity. More specifically, the levels thereof reached their peak values on
the
Gt'' day, which were on the order of G times and 4.4 times that observed for
the un-infected animals. The treatment of the infected animal group with
ambroxol permitted rapid and significant increase in the concentrations of
MPI and SP-A after one day from the administration of ambroxol and
reached their peak values on the order of 9 to 10 times and 8.4 times those
observed for the un-infected animals. In the group in which infected mice
were treated with ambroxol at a dose of 10 mg/kg/day, the levels of MPI and
SP-A were rapidly increased on the 15' day, thereafter they were gradually
increased, they reached the peak values on the 5"' day and they were
maintained at high levels until the 7"' day. However, when mice were treated
with 30 mg/kg/day of ambroxol, the levels of MPI and SP-A were rapidly
increased on the 1St day, reached the maximum values on the 4t'' day and
then MPI and SP-A rapidly disappeared. It was also observed that even the
secretion of SP-A and MPI in the un-infected group of mice were lightly
promoted by the administration of ambroxol.
Table 1
Regulatory Dose of ambroxolDa s after
virus-infection
~~
Factor [m /k Iday] 0 1 2
Tryp sin-like0 25.0 10.038.4 ~- 70.0 8.
2. 9 8
protease activity10 56.02.3* 81.010.0
[ a Ulml] 30 60.0 10.0* 90.0 12.5
~P_A [nglml] 0 I 2,10 6 2,30.1 6.0-!-2.1
I I I
10 9.43.9* 14.52.6*
30 11.31.1* 14.53.3*
22
CA 02459492 2004-03-03
MPI [u U/ml] 0 110.05G.0 123.0-25.0188.6G1.0
10 200.020.0*396.7G2.G*
30 305.0 18.3*518.3 183.0*
Table 1 (continued)
RegulatoryDa s after
virus-infection
Factor 3 4 5 6 7
Trypsin-like99.028.3 125.02.9 146.821.0 160.021.0 124.030.0
protease 135.017.0 156.625.0 201.520.0*172.030.0 17_5.026.0
act.
[~cUlml] 129.033.7 221.5~-38.0*148.0-19.8137.017.0 53.015.0*
SP-A[ng/ml]8.G~-3.2 9.2-4.6 10.4-!-2.212.51.5 7.31.9
14.82.9 15.63.4 19.13.5* 1G.53.1 15.13.1*
16.05.1 21.16.0* 12.41.2 12.11.7 4.91.5
MPI [ ~c 256.0 360.0 425.0 143.0 329.0
U/ml] 71.4 97.0 120.0 69.0 81.0
480.0 587.6 933.0 600.098.0 GG0180.0*
120.0* 147.0* 170.0*
753.0 929.295.0*800.0 500.061.0 156.030.0*
21G.0* 134.0*
The data in this table are expressed in terms of the average~SD. n = 5 for
each data. The significant difference between the ambroxol-treated group
and the group free of such a treatment, for each day, was evaluated by the
Student's t-Test. *P<0.05.
Table 2
Regulatory Dose of ambroxolDa s after
virus-infection
Factor [m Ik /day] 0 1 2
Trypsin-like 0 25.02.0 25.0-1.8 20.01.5
protease activity10 26.7 ~- 30.0-!-10.0
3.0
[u Ulml] 30 26.72.4 33.4--18.0
SP-A [ng/ml] 0 2.20.3 2.40.8 2.7-!-1.1
10 3.00.9 3.4l.l
30 3.91.7 5.21.0*
MPI [ a U/ml]0 112.530.0 125.0- 2G.0130.0- 50.0
10 150.0 40.0200.0 50.0
30 200.060.0 250.070.0
Table 2 (continued)
Regulatory Da s after virus-infection ~ .
Factor 3 4 5 G 7
23
CA 02459492 2004-03-03
~ypsin-like20.05.0 25.0G.0 25.08.0 20.0-!-10.025.0-8.0
protease 33.41.G* 55.0-1G.0*50.013.0* 20.09.1 25.010.0
act.
U/
ml] 40.011.0* G0.022.0* 25.010.0 20.07.7 20.06.0
[u 2.41.0 2.7-!-0.9 2.3-1-0.7 2.70.8 2.5--1.0
SP-A[ng/ml)
4.22.2 5.6 1.4* G.8-!-3.0*G.2-!-2.2*7.4~- 3.1*
5.G-!-1.9* 8.31.2* 7.23.1* G.92.8* 6.62.1*
MPI [ a 1G7.0~40.0 200.098.0 130.032.0 200.050.0 165.050.0
U/ml] 250.0-G0.0*300.0-!-50.0*500.0-!-70.0*470.8-x-50.0*430.0
100.0*
458.560.0* 550.080.0*50060.0* 250.080.0 167.070.0
The data in this table are expressed in terms of the average~SD. n = 5 for
each data. The significant difference between the ambroxol-treated group
and the group free of such a treatment, for each day, was evaluated by the
Student's t-Test. *P<0.05.
Then the effect of ambroxol on the secretion of mucosal
immunoglobulins IgA and IgG in BALF was investigated (see Figs. 3 and 4).
Fig. 3 shows the secretion-promoting effect of ambroxol on the level of
mucosal immunoglobulin IgA in BALF of (A) a group of un-infected mice and
(B) a group of mice infected with influenza A virus. In respect of the data
shown in this figure, the levels of IgA present in BALF of mice belonging to
the un-infected group (A) and the infected group (B) treated with an aqueous
common salt solution (white bar), and IO mg/kg/day (black bar) and 30
mg/kg/day (shadowed bar) of ambroxol were monitored over 7 days. These
data are expressed in terms of the average~SD (n = 5). According to the
Student's t-Test, the significant differences between the mice treated with
the aqueous common salt solution and ambroxol were found to be *P<0.05
and '*'~P<0.01.
Fig. 4 shows the secretion-promoting effect of ambroxol on the level of
mucosal immunoglobulin IgG in BALF of (A) a group of un-infected mice and
(ti) a group of mice infected with int~.uenza A virus. In respect of the data
shown in this figure, the levels of IgA present in BALF of mice belonging to
24
CA 02459492 2004-03-03
the un-infected group (A) and the infected group (B) treated with an aqueous
common salt solution (white bar), and 10 mglkg/day (black bar) and 30
mg/kg/day (shadowed bar) of ambroxol were monitored over 7 days. These
data are expressed in terms of the average~SD (n = 5). According to the
Student's t-Test, the significant difference between the mice treated with the
aqueous common salt solution and ambroxol was found to be *P<0.05.
The intra-nasal inoculation of influenza virus could considerably
promote the secretion of mucous immunoglobulins IgA and IgG. The levels of
these antibodies has been recognized to be correlated with the degree of the
virus-proliferation-inhibition (Liew FY, Russell SM, Appleyard G, Brand CM,
Beale J, Cross-protection in mice infected with influenza A virus by the
respiratory route is correlated with local IgA rather than serum antibody or
cytotoxic T cell reactivity, Eur. J. Immunol., 1984, 14: 350-356; Tamura S,
Funato H, Hirabayash Y, et al., Functional role of respiratory tract
haemagglutinin-specific IgA antibodies in protection against influenza,
Vaccine, 1990, 8: 479-485).
The IgA concentration in BALF derived from the group of un-infected
mice is very low on the order of 10.3~6.6 ng/ml, while the IgG concentration
is relatively high on the order of 460~26.2 nm/ml. This relatively high IgG
level may be due to the diffusion thereof from the serum to the fluid secreted
in the respiratory tract (see Figs. 3A and 4A). The treatment of the group of
un-infected mice with 10 and 30 mg/kg/day of ambroxol promoted the IgA
secretion. More specifically, the treatment increased the concentration
thereof to a level of about 10 times that observed for the group free of such
a
treatment on the 7t'' and 5t'' day, respectively, from the initiation of the
treatment and the treatment slightly increased the concentration of IgG to a
ievei of abuut 1.2 time tllat Ubselved iir tile group fr2e of SW 11 a
treatW2nt Oi~
the 7"' and Gt'' day from the initiation of the treatment. If infecting mice
with
CA 02459492 2004-03-03
influenza virus, the concentrations of IgA and IgG in BALF substantially
increased after one to two days from the infection, the levels thereof reached
their peaks or the level of IgA on the 7th day was found to be about 400 times
and the level of IgG on the Gth day was found to be about 11 times those
observed for the group free of such a treatment (Figs. 3B and 4B). The
treatment of the infected mice with 10 and 30 mg/kg/day of ambroxol
significantly increased the IgA levels on the 7t'' day and 5t'' day to about
G00
times and 700 times, respectively, that observed for the basic concentration
of IgA. On the other hand, the treatment of the infected mice with 10 and 30
mg/kg/day of ambroxol medially stimulated the IgG secretion in the infected
mice or the concentrations thereof on the G"' day and 5''' day were found to
be
about 1G times and 15 times that of the basic concentration of IgG. These
results might be obtained because of the considerable promotion of the
mucosal immunoglobulin IgA secretion and the medium promotion of the IgG
secretion, which were induced by the infection, through the treatment with
ambroxol. Therefore, it would be recognized that these increases of the
immunoglobulin levels were the results of the virus-proliferation-inhibitory
effect of ambroxol in the respiratory tract.
5) Effect of Ambroxol on Release of Cytokines
There has been reported that ambroxol inhibits, in vitro, any release
of inflammatory cytokines such as TNF- a , IL-2, IL-l, IL-4, IL-13 and IFN-
y (Pfeifer S, Zissel G, Kienast K, Muller-fluernheim J., Reduction of
cytokine release from blood and bronchoalveolar mononuclear cells by
ambroxol, Eur. J. Med. Res., 1997, 2: 129-132; Gibbs BF, Schmutzler W,
Vollrath IB, Brostharardt P, Braam U, Wolff HH, Zadlo-Klarwasser G.,
Ambroxol inhibits the release of histamine, leukotrienes and cytokines from
human leukocytes and mast ceiis, Infiamm. Res. 1999; 4~: $G-93). To
determine the anti-inflammatory effect of ambroxol in the mice infected with
2G
CA 02459492 2004-03-03
influenza virus, the inventors of this invention investigated or analyzed the
levels of mucosal immune-promoting cytokines, for instance, inflammatory
cytokines such as TNF- a , IL-4 and INF- y , IL-6 and IL-12 (Boyaka PN,
Marinaro M, Jackson R, Menon S, Kiyono H, Jirillo E, McGhee JR., IL-12 is
an effective adjuvant for induction of mucosal immunity, J. Immunol.,
1999,162:122-128). The results thus obtained are listed in the following
Table 3 (the effect of ambroxol on the cytokines such as TNF- cx , IL-12, INF-
v and IL-G in BALF derived from the mice infected with influenza
A/Aichi/G8 (H3N2) viruses.
The levels of the cytokines present in BALF derived from the un-
infected mice were lower than the detection limits. The infection with
influenza virus significantly induced the secretion of all of the cytokines
examined except for IL-4 in BALF, although the patterns thereof as a
function of the elapsed time were different from one another. More
specifically, when the animals were infected with influenza virus, the level
of
TNF- a was initially increased or it reached the peak level on the 1S' day,
thereafter it was rapidly reduced and it reached a secondary small peak on
the 6"' day. The level of IL-G was also rapidly increased on the 1s' day after
the infection, the level was maintained at such a high level and reached its
peak value on the 5"' day, but began to undergo rapid reduction on the 7"' day
after the infection. The concentrations of IL-12 and INF- y were gradually
increased after the administration of ambroxol and reached the respective
peak values on the 4"' and 6''' days after the administration thereof.
However,
IL-4 was not detected in BALF derived from the infected mice over seven
days examined (data were not shown). When the infected mice were treated
with ambroxol, there were observed the TNF- a , INF- y and IL-12-
secretion-inhibitory effects on 3~ to 5'~ day, the 1" day and 4"' day,
respectively, after the initiation of the treatment with ambroxol, but the
27
CA 02459492 2004-03-03
inhibitory effect was not always observed during the treatment with
ambroxol. On the other hand, the level of IL-G in BALF derived from the
infected mice was increased on the 4th and 6th days after the initiation of
the
treatment with ambroxol.
Table 3
Cytokine Dose of ambroxolDa s after
infection
with influenza
virus
(CK) (p (A1VI) (m 1 2 3
/ml) Ik /day)
T1~IT-a 0 155.536.2 124.2-27.8 67.7-1-7.3
10 150.6-!-21.3108.917.3 57.820.2
30 123.5-26.4 84.818.8 35.55.4*
IL.12 0 22.48.9 93.412.1 138.38.8
10 27.37.1 68._512.9* 133.31 17.2
30 22.44.1 _ 141.5 15.1
108.2-!-33.3
INF-v 0 17.52.6 12.62.3 3.90.8
10 9.42.4* 9.51.8 2.80.9
30 10.42.7* 9.82.4 4.01.1
IL-6 0 139.1 45.2 196.0 22.6 268.0 75.2
10 174.8-3_5.0 191.851.9 280.254.2
30 170.8 ~- 186. 7 19.6326.2 44.9
28.9
Table 3 (continued)
CK Dose Days after
of infection_with
influenza
virus
- -V
~
(pgl AM (mg 4 5 6 7
ml /k /
da
ThIT-0 28.90.2 57.11_5.8 64.1-!-29.3 12.35.2
~~
23.18.3 29.0-!-8.5* 61.124.0 9.82.3
_
30 19.23.3* 45.223.2 41.517.0 10.63.6
L- 0 184.78.5 74.721.9 32._64.7 88.333
12 10 119.515.8* 57.4_16.0_ 29.4--!-6.2 62.5
-27.7
30 118.611.4* 62.413.6 44.329.1 _
95.852.2
IFN- 0 7.1--0.9 40.4-!-10.8 49.5-!-2G.6 5.32.9
v 10 5.32.8 14.75.3* 39.418.6 4.01.6
30 10.25.5 32.811.1 61.821.7 5.11.8
IL-6 0 216.2 60.2459.8 127.1430.0 ~ 63.672.1 13.0
10 339.257.1* 540_.9--84.2503.2361.4 73.7-!-14.7
30 433.5 101.9*478.286.4 817.0 168.0*80.0 17.5
The data in this table are expressed in terms of the average~SD. n = 5 for
10 each data. The significant difference between the ambroxol-treated group
28
CA 02459492 2004-03-03
and the group free of such a treatment, for each day, was evaluated by the
Student's t-Test. kP<0.05.
<Consideration>
In this study, it has been concluded that ambroxol significantly
inhibits the influenza virus-proliferation in the respiratory tract and
likewise improves the surviving rate of mice infected with the lethal dose of
influenza A/Aichi/68 (H3N2) virus. Influenza virus shows organ specificity to
the respiratory tract and the pathogenicity and replication thereof are
determined by a variety of factors derived from the host cell and the immune
responses of T-cells and B-cells.
There have been reported that, in the respiratory tracts of animals,
the trypsin-type proteases such as tryptase Clara serves as a cellular factor,
which promotes the influenza virus-replication (Kido H, Yokogoshi Y, Sakai
K, Tashiro M, Kishino Y, Fukutomi A, Kutunuma N., Isolation and
characterization of a novel trypsin-like protease found in rat bronchiolar
epithelial Clara cells, J. Biol. Chem., 1992; 267:13573-13579; Tashiro M,
Yokogoshi Y, Tobita K, Seto JT, Rott R, Kido H. Tryptase Clara, an activating
protease for Sendai virus in rat lungs, is involved in pneumopathogenicity, J.
Virol., 1992, GG: 7211-7216) and that on the other hand, factors capable of
inhibiting the viral proliferation are MPI as an inhibitor of proteases (Beppu
Y, Imamura Y, Tashiro M, Towatari T, Ariga H, Kido H., Human Mucus
protease inhibitor in airway fluids is a potential defensive compound against
infection with influenza A and Sendai viruses, J. Biochem., 1997, 121: 309-
316) and PS, which adsorbs proteases to thus inhibit the activity thereof
(Kido H, Sakai K, Kishino Y, Tashiro M., A pulmonary surfactant is a
potential endogenous inhibitor of proteolytic activation of Sendai virus and
influenza virus, FEBS Lett., 1993, 322: 115-119). The concentration of the
29
CA 02459492 2004-03-03
trypsin-type protease in the usual environment of the respiratory tract is
maintained at the level permitting the infection with and proliferation of
influenza virus and is higher than those of inhibitors present therein.
PS covering the pulmonary alveolar epithelium is linked with tryptase
Clara to thus inhibit the activity of the protease (Kido H, Sakai K, Kishino
Y,
Tashiro M., A pulmonary surfactant is a potential endogenous inhibitor of
proteolytic activation of Sendai virus and influenza virus, FEBS Lett., 1993,
322: 115-119; Kido H, Murakami M, Oba K, Chen Y, Towatari T., Cellular
proteinases trigger the infectivity of the influenza A and Sendai viruses,
Mol.
Cells, 1999, 9: 235-244). The infection with influenza virus promoted the
secretion of both trypsin-type protease required for the proliferation of the
virus and the inhibitor thereof. Moreover, when the infected mice were
treated with ambroxol, the secretion of the foregoing substances was further
promoted significantly, but the effect changed the balance between the
protease and the inhibitor. The concentration of the protease induced by the
viral infection was further increased to a level of 1.3 to 1.4 times, while
those
of SP-A and MPI were increased to a level of 1.5 to 1.? times and 1.9 times,
respectively by the treatment with ambroxol. These results clearly indicate
that the treatment with ambroxol permits the rate of the substances showing
virus-proliferation-inhibitory effects and present in the fluid secreted in
the
respiratory tract of the infected mice and that the treatment improves the
environment in the respiratory tract in such a manner that it has a high
virus-proliferation-inhibitory tendency as compared with the environment in
the respiratory tract of un-treated infected mice.
Moreover, ambroxol had an effect of promoting or increasing the
release of mucosal immunoglobulins IgA and IgG in the infected and un-
infected mice as shown in Fig. 3. This drug also medially promoted the
secretion of IgG (Fig. 4). Ambroxol likewise promoted the release of IgA even
CA 02459492 2004-03-03
in the un-infected mice. More specifically, the concentration of IgA was
increased to about 10 times the basic concentration thereof and that of IgG
was increased to 1.2 times the basic concentration. After the viral infection,
the concentrations of IgA and IgG in BALF were considerably increased, but
the treatment of the infected mice with ambroxol could increase the
concentrations of IgA and IgG to levels of about 1.5-1.8 times and 1.45 times,
respectively, the maximum concentrations thereof induced through the viral
infection. This clearly indicates that the increases in the concentrations of
IgA and IgG due to the treatment with ambroxol play an important role in
the improvement of the surviving rate of the infected mice.
The precise mechanism of ambroxol to promote the secretion of a
variety of factors such as IgA and IgG, SP-A, MPI and trypsin-type proteases
has not yet been clearly elucidated, but the foregoing facts suggest that
ambroxol would stimulate a plurality of target cells of the upper and lower
respiratory tracts. When mice were treated with ambroxol in the optimum
dose of 10 mglkglday, the concentrations of the virus-proliferation-inhibitory
substances and those of immunoglobulins in the respiratory tract were
gradually increased with the elapsed time and the concentrations thereof
were maintained at such high levels on the '7th day when virus-replication
was ceased. However, the treatment with a higher dose of ambroxol rapidly
increased the concentrations of these substances and the latter quickly
reached their peak levels on the 4'" to 5'h day, but such high levels thereof
could not be maintained throughout the viral infection. This would be a
cause of such a low virus-proliferation-inhibitory effect of ambroxol at a
dose
of 30 mg/kg/day. These results indicate that ambroxol promotes the secretion
of the inhibitory substances and the trypsin-type proteases rather than
promotes the synthesis of these substances in the fluid of the respiratory
tract. Moreover, one would be recognized that these virus-proliferation-
31
' CA 02459492 2004-03-03
inhibitory substances should be maintained at such high levels over 7 days to
improve the surviving rate of the infected mice.
The viral proliferation was ceased on the 7'" day (see Fig. 2), but the
inflammation of the lung was maintained and even made slow progress.
Recently, a variety of studies have made it clear that ambroxol possesses an
anti-inflammatory effect (Gillissen A, Scharling B, Jaworska M, Bertling A,
Rasche K, Schultze- Werninghaus G., Oxidant scavenger function of
ambroxol in vitro: a comparison with N-acetylcysteine AC, Res. Exp. Med.
(Berl.), 1997, 196: 389-398) and permits the reduction of the ability of
producing inflammatory cytokines (Pfeifer S, Zissel G, Kienast K, Muller-
~uernheim J., Reduction of cytokine release from blood and bronchoalveolar
mononuclear cells by ambroxol, Eur. J. Med. Res., 1997, 2: 129-132; Gibbs
BF, Schmutzler W, Vollrath IB, Brostharardt P, Braam U, Wolff' HH, Zadlo-
Klarwasser G., Ambroxol inhibits the release of histamine, leukotrienes and
cytokines from human leukocytes and mast cells, Inflamm. Res., 1999, 48:
8G-93). In this study, it has been recognized that ambroxol inhibits the
levels
of inflammatory cytokines or THF- a and IFN- v in the fluid secreted in the
respiratory tract of the infected mice, but the effect is not always observed
throughout the viral infection. Moreover, it has been reported that both IL-G
and IL-12 possess an effect of promoting the mucous immune and in
particular, it has been reported that IL-12 has an effect of promoting the
production of the mucous immunoglobulin IgA (Boyaka PN, Marinaro M,
Jackson R, Menon S, Kiyono H, Jirillo E, McGhee JR., IL-12 is an effective
adjuvant for induction of mucosal immunity, J. Immunol., 1999,162:122-128).
The treatment of the infected mice with ambroxol increased the levels of IL-
G in BALF on the 4t" day and Gt" day and temporarily inhibited the level of
iL-12 on the 4'" day
On the one hand, arnbroxol showed effects, which ara unfavorable for
32
CA 02459492 2004-03-03
the bio- defensive system against the influenza virus, such as an effect of
increasing the level of the trypsin-type proteases and an effect of temporal
inhibition of any release of IL-12, but the treatment with ambroxol, on the
whole, considerably increased the concentrations of biological factors
showing the virus-proliferation-inhibitory effect in the fluid secreted in the
respiratory tract and as a result, it could inhibit the viral proliferation in
the
respiratory tract to thus significantly improve the surviving rate of the mice
infected with influenza viruses. Among these, the effect of ambroxol involved
in the inhibition of influenza virus proliferation would be proved by the
increase in the concentrations of, for instance, SP-A, MPI, IgA and IgG in the
respiratory tract and the inhibition of any release of inflammatory cytokines
in the respiratory tract. These results suggest that ambroxol can clinically
be
used for the treatment of subjects infected with influenza A virus or
prevention of influenza A virus infection.
In general, there is such a tendency that influenza prevails and the
prevalence thereof, in most cases, goes into headlines. Therefore, the anti-
infl.uenzal agent of the present invention can be used as a therapeutic agent
immediately after the prevalence was informed, and also even after the
infection. In particular, the agent for treating subjects infected with
influenza virus or preventing the infection therewith according to the
present invention can effectively be applied to the treatment or prevention of
diseases caused by causal viruses, which have outer membrane glycoproteins
and infect the respiratory tract to thus undergo proliferation, such as
influenza viruses.
33
